Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 1:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,585 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections

NCT05750589
Conditions
Retinal Disease
Interventions
IRX-101, Providone-Iodine
Drug
Lead sponsor
iRenix Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Retinal Vein Occlusion
Interventions
Aflibercept Ophthalmic
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Recruiting No phase listed Observational Accepts healthy volunteers

EyeConic: Qualification for Cone-Optogenetics

NCT05294978
Conditions
Retinal Dystrophies
Interventions
Optical coherence tomography (OCT)
Diagnostic Test
Lead sponsor
Institute of Molecular and Clinical Ophthalmology Basel
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
San Francisco, California • Miami, Florida • Pittsburgh, Pennsylvania
Conditions
Geographic Atrophy
Interventions
SAR446597, Sham Comparator
Drug
Lead sponsor
Sanofi
Industry
Eligibility
60 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
14
States / cities
Peoria, Arizona • Scottsdale, Arizona • Gainesville, Florida + 10 more
Conditions
Macular Degeneration, Age Related, Geographic Atrophy
Interventions
Spectralis FAF imaging, Optos imaging, Zeiss Clarus 700 imaging
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab, Laser
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Up to 6 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
32
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Irvine, California + 26 more
Completed Not applicable Interventional

Macular Degeneration and Aging Study

NCT02224963
Conditions
Age-related Macular Degeneration
Interventions
Preventive Problem-Solving Training, Life and Health Review
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Rochester, New York
Conditions
Retinal Disease, Healthy
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Results available

An Extension to Study MD7108240

NCT00733304
Conditions
Macular Degeneration
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Beverly Hills, California • Sacramento, California • Winter Haven, Florida + 5 more
Conditions
Retinoblastoma
Interventions
Questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Macular Edema
Interventions
AR-1105-CF1, AR-1105-CF2
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Palo Alto, California + 8 more
Completed Not applicable Interventional Accepts healthy volunteers

The Diabetes TeleCare Study

NCT00288132
Conditions
Diabetes Mellitus, Type 2
Interventions
Intervention, Usual Care
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bennettsville, South Carolina
Conditions
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema, Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Interventions
INV-102
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Diabetic Macular Edema
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
48
States / cities
La Jolla, California • Redlands, California • Santa Maria, California + 44 more
Completed Not applicable Interventional

Scotoma Perimetry Oculomotor Training

NCT05456581
Conditions
Macular Degeneration, Central Visual Impairment
Interventions
'Scotoma awareness' Training, Control Training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Withdrawn Not applicable Interventional Accepts healthy volunteers

Erythrocyte Ghost Mediated Retinal Diagnosis

NCT02445001
Conditions
Retinal Disease
Interventions
ICG loaded erythrocytes
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
40 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Cardiovascular Autonomic Neuropathy, Diabetic Autonomic Neuropathy, Autonomic Dysfunction
Interventions
ANSAR ANX 3.0 Software
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Not listed Not applicable Interventional Accepts healthy volunteers

Pistachios and Neural Macular Pigment

NCT05283941
Conditions
Macular Degeneration, Retinal Degeneration, Retinal Diseases, Eye Diseases
Interventions
Pistachio Group
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
40 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Age-Related Macular Degeneration
Interventions
SF0166 Topical Ophthalmic Solution
Drug
Lead sponsor
OcuTerra Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Fullerton, California • Mountain View, California + 9 more
Conditions
Stargardt's Disease
Interventions
Long term follow up in all patients who received SAR422459 in previous study TDU13583
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2033
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Retinal Degeneration, Retinal Diseases, Eye Diseases, Geographic Atrophy, Pathological Conditions, Anatomical
Interventions
Dapagliflozin, Matching Placebo
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Fomivirsen sodium
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Los Angeles, California • Pasadena, California • San Francisco, California + 11 more
Conditions
Leber Congenital Amaurosis
Interventions
Not listed
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Macular Edema
Interventions
Dexamethasone Phosphate Ophthalmic
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts